Last reviewed · How we verify
NCT05025761
A Personal Protection Package for Reducing Malaria Transmission in Forest-going Mobile and Migrant Populations in Myanmar: A Stepped-wedge Trial With Nested Mixed-methods Study
NA trial testing Personal protection package in Plasmodium Falciparum Infection in 1,200 participants. Status unknown.
1 June 2022
Quick facts
| Lead sponsor | Macfarlane Burnet Institute for Medical Research and Public Health Ltd |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 1,200 |
| Start date | 1 January 2022 |
| Primary completion | 1 June 2022 |
| Estimated completion | 1 June 2022 |
Drugs / interventions tested
- Personal protection package
Conditions studied
- Plasmodium Falciparum Infection — all drugs for Plasmodium Falciparum Infection →
Sponsor
Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Who can join
18 and older, any sex, with Plasmodium Falciparum Infection. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Plasmodium spp. infection diagnosed by RDT
Time frame: Assessed weekly, longitudinally over 12 months
Change in the number of Plasmodium spp. infections detected by RDT per week per village (SD Bioline P.f/P.v)
Sponsor's own description
This stepped-wedge cluster-randomized controlled trial with nested mixed methods study will assess the effectiveness, acceptability, feasibility and cost effectiveness of a personal protection package to reduce malaria transmission among mobile and migrant populations (MMPs) and the general population in their residing villages in Myanmar.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05025761
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Macfarlane Burnet Institute for Medical Research and Public Health Ltd trials
Trials by the same sponsor.
- NCT05874271 — Short Course Primaquine for the Radical Cure of P. Vivax - Papua New Guinea · NA · completed
- NCT05264558 — Preparing for the Final Phase of Hepatitis C Elimination. Cairns Final 30% · Phase 4 · completed
- NCT05323799 — The Optimising Isolation, Quarantine and Distancing Study for COVID-19 (Optimise) · unknown
- NCT07337382 — The Optimising Isolation, Quarantine and Distancing Study for COVID-19 · active not recruiting
- NCT04510246 — Link Hepatitis C Notifications to Treatment in Tasmania · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05025761 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Macfarlane Burnet Institute for Medical Research and Public Health Ltd
- Last refreshed: 2 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05025761.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing